Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Otago researchers receive new joint research funding


Thursday 2 March 2017

Otago researchers receive new joint pharmaceuticals research funding

Researchers from University of Otago are among the first recipients of two new grants from PHARMAC and the Health Research Council of New Zealand (HRC).

Dr Lianne Parkin of the Department of Preventive and Social Medicine receives a grant worth more than $210,000 for research into metformin use by people with diabetes. This drug is the first-line treatment for type 2 diabetes, however overseas research shows that many patients do not use it as prescribed.

Dr Parkin and colleagues will explore how to improve the way New Zealanders with type 2 diabetes use metformin.

PHARMAC Chief Executive Steffan Crausaz and HRC Chief Executive Professor Kath McPherson announced the first recipients of the joint fund today.

Mr Crausaz says the two studies will provide valuable insights into how New Zealanders can get the best out of medicines.

“Our objective in setting up the fund with the HRC was to improve our knowledge of medicines use in New Zealand, so that we can take steps to improve people’s use of medicines,” he says.

“Metformin is an important medicine for people with type 2 diabetes, so Dr Parkin’s research will give us a better idea as to why people might not continue taking the medicine they need to keep them well.”

Dr McPherson says the collaboration with PHARMAC is providing a further opportunity to grow innovative research into pharmaceuticals in New Zealand.

“We’re delighted to be involved in this research initiative with PHARMAC. This is a great example of government health organisations collaborating to benefit patients and strengthen the use of research evidence to improve our health system overall.

“I’m confident that the studies funded through this partnership initiative will be of a high quality and add to our knowledge of how New Zealanders use medicines.”

Project details:

Improving metformin adherence and persistence in people with type 2 diabetes
$213,229, 24 months

Principal Investigator: Dr Lianne Parkin. The other investigators are Dr Simon Horsburgh (Preventive and Social Medicine), Mr Dave Barson (Preventive and Social Medicine), Associate Professor Katrina Sharples (Mathematics and Statistics, and Medicine), Dr Jimmy Zeng (Preventive and Social Medicine), Dr Lisa Te Morenga (Associate Dean (Māori), Division of Sciences; Edgar Diabetes and Obesity Research Centre; Human Nutrition), Faumuina Associate Professor Fa’afetai Sopoaga (Associate Dean (Pacific), Division of Health Sciences; Preventive and Social Medicine). Five of the researchers are core members of the Pharmacoepidemiology Research Network at the University.

Type 2 diabetes imposes a substantial burden on New Zealanders, particularly Māori and Pacific peoples. Metformin is the first-line medication for the treatment of type 2 diabetes, but overseas research has found that many patients have suboptimal metformin adherence and persistence. Persistence refers to whether a person stays on a therapy, while adherence refers to whether a person takes a medication according to the prescribed schedule. Suboptimal metformin adherence and persistence are important because they are associated with a higher risk of diabetes complications.

The researchers will use routinely collected health data to (a) describe the patterns of metformin adherence and persistence in New Zealanders with type 2 diabetes, and (b) investigate the predictors and consequences of suboptimal adherence and persistence. They will also interview people with type 2 diabetes to get their views on what helps, and hinders, good metformin adherence and persistence. The findings will contribute to improved outcomes for people prescribed metformin.

ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Statistics: Business Research And Development Up 29 Percent

Computer services and machinery manufacturing firms led the way in an almost 30 percent lift in business spending on research and development (R&D) in 2016, Stats NZ said today. Businesses spent $1.6 billion on R&D in 2016, up $356 million (29 percent) from 2014. More>>

ALSO:

China Shopping: NZ-China FTA Upgrade Agreed Among Slew Of New Deals

New Zealand Prime Minister Bill English and China Premier Li Keqiang signed off a series of cooperation deals spanning trade, customs, travel and climate change and confirmed commencement of official talks on an upgrade to the nine-year old free-trade agreement between the two countries. More>>

ALSO:

Media: TVNZ Flags Job Cuts To Arrest Profit Decline

Chief executive Kevin Kenrick said the changes were aimed at creating "a sustainable future video content business for TVNZ in an ever-changing media market." More>>

ALSO:

Reserve Bank: Wheeler Keeps OCR At 1.75%

Reserve Bank governor Graeme Wheeler kept the official cash rate unchanged at 1.75 percent, as expected, and reiterated his view that the benchmark rate doesn't need shifting for the foreseeable future. More>>

ALSO:

Trade Plans: Prime Minister's Speech To International Business Forum

"The work to improve public services, build infrastructure, and solve social problems is possible only because we have enjoyed sustained, solid economic growth. A big reason for that is the Government’s consistent agenda of economic reform, and our determination to open up more opportunities for trade with the world." More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news